Results 251 to 260 of about 94,246 (299)

Pachymaran alleviates fat accumulation, hepatocyte degeneration, and injury in mice with nonalcoholic fatty liver disease. [PDF]

Open Med (Wars)
Yu H, Wan M, Li H, Liu X.
europepmc   +1 more source

Evaluation of Pathogenic Variants Associated With Monogenic Disorders of Dyslipidemia in Patients With Well Characterised MASLD

Liver International, Volume 46, Issue 2, February 2026.
ABSTRACT Background and Aims Dyslipidemia is common in patients with MASLD, but the frequency and significance of inherited disorders of dyslipidemia are unclear. We investigated the prevalence and significance of pathogenic variants associated with selected monogenic disorders of dyslipidemia in 3358 patients with well‐characterised MASLD. Approach We
Tae‐Hwi Schwantes‐An, Marco A. Abreu, Brent A. Neuschwander‐Tetri, Jian Wang, Xiuqing Guo, Jingyi Tan, Robert A. Hegele, Nicholas O. Davidson, Luca Lotta, Niek Verweij, Katherine P. Yates, Jerome I. Rotter, Naga Chalasani   +12 more
wiley   +1 more source

Major Depression as a Catalyst for Nonalcoholic Fatty Liver Disease: Insights From a Comprehensive Mendelian Randomization Study. [PDF]

Can J Gastroenterol Hepatol
Su Y, Lin S, She L, Xiong J, Ding Y, Zhang Y, Chen Y.   +6 more
europepmc   +1 more source

Gpx4 Deletion‐Mediated Macrophage Ferroptosis Alleviates Obesity‐Associated Insulin Resistance

The FASEB Journal, Volume 40, Issue 2, 31 January 2026.
Macrophage‐specific loss of Gpx4 induces ferroptosis, thereby alleviating high‐fat diet (HFD)‐induced obesity, insulin resistance, and metabolic dysfunction, and conferring systemic metabolic protection in type 2 diabetes (T2D). ABSTRACT Obesity has become a global epidemic and a major contributor to the development of Type 2 diabetes (T2D) through the
Suhua Wu, Juan Peng, Xiaodong Wang, Hong Gao, Huangrui Fang, Shiyi Hu, Qiufen Wei, Yuanye Dang, Haixia Tu, Mingyan Zhu, Jianye Peng, Yumiao Liu, Gaofeng Zeng, Xiaoyan Dai   +13 more
wiley   +1 more source

Carvacrol-Loaded Chitosan Nanoparticles as a Multifunctional Nanotherapeutic Strategy Targeting Oxidative Stress, Inflammation, Apoptosis, and Genotoxicity in Nonalcoholic Fatty Liver Disease. [PDF]

Antioxidants (Basel)
Alfawaz M, Elmorsy EM, Alshammari AN, Hakim NA, Jawad NMM, Hassan SA, Fawzy MS, Esmaeel SE.   +7 more
europepmc   +1 more source

What is the role of nonalcoholic fatty liver disease in pulmonary carcinoma development? [PDF]

World J Gastroenterol
Pan Q, Xu QY, Zhang LH, He YF.
europepmc   +1 more source

Engineered Hydrogels for Organoid Models of Human Nonalcoholic Fatty Liver Disease. [PDF]

Adv Sci (Weinh)
Liu Y, Gilchrist AE, Johansson PK, Guan Y, Deras JD, Liu YC, Ceva S, Huang MS, Navarro RS, Enejder A, Peltz G, Heilshorn SC.   +11 more
europepmc   +1 more source

Increased risk of nonalcoholic fatty liver disease in patients with thyroid cancer: a nationwide cohort study. [PDF]

BMC Cancer
Cho YB, Park KS.
europepmc   +1 more source

Peri-Complication Diagnosis of Nonalcoholic Fatty Liver Disease: A US Population-Based Retrospective Analysis.

Dig Dis
Manikat R, Tran S, Kam LY, Dronamraju D, Cheung R, Nguyen MH.   +5 more
europepmc   +1 more source